Therefore, based on these findings, we can predict that the fusion peptide expressed by VACV is able to induce the activity of cytotoxic CD8+ effector T cells, according to the ex vivo data presented above, and therefore the structure of the fusion protein provides a new strategy for the tumor antigen-based peptide vaccine design. Here, CD8A is linked to neoplasm.